Bone Biologics (BBLG) Share-based Compensation (2014 - 2026)
Bone Biologics (BBLG) posted quarterly Share-based Compensation of $45674.0 for Q4 2025, down 54.67% year-over-year from $100754.0 in Q4 2024, and down 47.61% quarter-over-quarter from $87180.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Share-based Compensation (2014 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Share-based Compensation for 10 consecutive years, with $45674.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 54.67% year-over-year to $45674.0; the TTM figure through Dec 2025 stood at $256358.0 (up 35.77% YoY), while the FY2025 annual figure was $256358.0, up 35.77% from the prior year.
- Share-based Compensation eased to $45674.0 in Q4 2025 per BBLG's latest filing, from $87180.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $152844.0 in Q1 2022 and bottomed at $16670.0 in Q2 2023.
- Historically, Share-based Compensation has averaged $54025.6 across 4 years, with a median of $48139.5 in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 70.71% — and 2025, when it surged 385.93%.
- Bone Biologics' Share-based Compensation stood at $62507.0 in 2022, then rose by 13.81% to $71139.0 in 2023, then soared by 41.63% to $100754.0 in 2024, then slumped by 54.67% to $45674.0 in 2025.
- Business Quant data shows BBLG's Share-based Compensation at $45674.0 in Q4 2025, $87180.0 in Q3 2025, and $72899.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 4.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 106,479.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 106,479.00 |
| Dec 31, 2025 | 45,674.00 |
| Sep 30, 2025 | 87,856.00 |
| Jun 30, 2025 | 87,856.00 |
| Mar 31, 2025 | 275,412.00 |
| Dec 31, 2024 | 100,754.00 |
| Sep 30, 2024 | 166,290.00 |
| Jun 30, 2024 | 74,151.00 |
| Mar 31, 2024 | 74,151.00 |
| Dec 31, 2023 | 71,139.00 |
| Sep 30, 2023 | 274,284.00 |
| Jun 30, 2023 | 16,995.00 |
| Mar 31, 2023 | 509,454.00 |
| Dec 31, 2022 | 62,507.00 |
| Sep 30, 2022 | 452,829.00 |
| Jun 30, 2022 | 342,294.00 |
| Mar 31, 2022 | 342,294.00 |
| Dec 31, 2021 | 1,023.00 |
| Dec 31, 2020 | 226,418.00 |
| Sep 30, 2020 | 566,045.00 |